` ZYME (Zymeworks Inc) vs S&P 500 Comparison - Alpha Spread

ZYME
vs
S&P 500

Over the past 12 months, ZYME has significantly outperformed S&P 500, delivering a return of +94% compared to the S&P 500's +13% growth.

Stocks Performance
ZYME vs S&P 500

Loading
ZYME
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ZYME vs S&P 500

Loading
ZYME
S&P 500
Difference
www.alphaspread.com

Performance By Year
ZYME vs S&P 500

Loading
ZYME
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Zymeworks Inc vs Peers

S&P 500
ZYME
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Zymeworks Inc
Glance View

Market Cap
2B USD
Industry
Biotechnology

Zymeworks Inc. is a biopharmaceutical company. The company is headquartered in Middletown, Delaware and currently employs 286 full-time employees. The company went IPO on 2019-06-24. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The firm operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. The Company’s ZymeLink is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.

ZYME Intrinsic Value
13.49 USD
Overvaluation 48%
Intrinsic Value
Price
Back to Top